Joseph S. Carroll - 01 Dec 2022 Form 4 Insider Report for Renovacor, Inc.

Reporting relationship: Chief Accounting Officer
Issuer ticker: N/A
Reported as of: 01 Dec 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Dec 2022, 20:20:48 UTC
Prior SEC filing: 21 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Joseph Carroll

Key filing fact

Joseph S. Carroll filed Form 4 for Renovacor, Inc. on 05 Dec 2022.

Key facts

This page summarizes Joseph S. Carroll's Form 4 filing for Renovacor, Inc..
4 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 05 Dec 2022, 20:20.

Change

Previous filing in this sequence was filed on 21 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RCOR transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -8,195
Change %: -100%
Price
Shares after: 0
Date: 01 Dec 2022
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RCOR transaction Derivative

Stock Option

Disposed to Issuer

Transaction value: $0
Shares: -25,884
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 01 Dec 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,884
Exercise price
Footnotes: F2, F3

RCOR transaction Derivative

Stock Option

Disposed to Issuer

Transaction value: $0
Shares: -16,350
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 01 Dec 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,350
Exercise price
Footnotes: F2, F3

RCOR transaction Derivative

Stock Option

Disposed to Issuer

Transaction value: $0
Shares: -29,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 01 Dec 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 29,000
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Joseph S. Carroll is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

Represents shares of common stock underlying Company Time-Vesting RSUs (as defined in the Agreement and Plan of Merger, dated as of September 19, 2022, by and among the Issuer, Rocket Pharmaceuticals, Inc. ("Rocket") and the other parties thereto (the "Merger Agreement")). Each unvested RSU outstanding immediately prior to the First Effective Time (as defined in the Merger Agreement) was accelerated, cancelled and converted into the right to receive a number of Rocket common stock, rounded to the nearest whole number, equal to the number of shares of Issuer common stock underlying such Company Time-Vesting RSU multiplied by the Exchange Ratio (as defined in the Merger Agreement).

Footnote F2

Represents Company Options (as defined in the Merger Agreement), whether vested or unvested, that were assumed by Rocket in the merger and replaced with an option to purchase a number of Rocket common stock equal to the product of (A) the number of Issuer shares subject to such Company Option as of immediately prior to the First Effective Time (as defined in the Merger Agreement), multiplied by (B) the Exchange Ratio, rounded down to the nearest whole number of Rocket common stock, at an exercise price per Rocket common stock underlying such option equal to the quotient obtained by dividing (x) the per share exercise price of Company Options immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent.

Footnote F3

Each Company Option described herein shall be subject to the same terms and conditions as applied to the corresponding Company Option as of immediately prior to the First Effective Time, except as otherwise provided in the Merger Agreement.